16.12.2012 Views

Therapies for Children With Autism Spectrum Disorders

Therapies for Children With Autism Spectrum Disorders

Therapies for Children With Autism Spectrum Disorders

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Evidence Table. <strong>Therapies</strong> <strong>for</strong> children with ASD (continued)<br />

Study<br />

Description Intervention<br />

Whalen et al.,<br />

2010 (continued)<br />

Author:<br />

Adams et al.,<br />

2009 (A)<br />

Adams et al.,<br />

2009 (B)†<br />

Country:<br />

US<br />

Practice<br />

setting:<br />

Academic<br />

Intervention<br />

setting:<br />

Clinic<br />

Enrollment<br />

period:<br />

NR<br />

Funding:<br />

Defined protocol<br />

followed:<br />

Yes<br />

Measure of treatment<br />

fidelity reported:<br />

No<br />

Co-interventions held<br />

stable during treatment:<br />

NR<br />

Concomitant therapies,<br />

n (%):<br />

G1: speech , language &<br />

occupational interventions<br />

delivered but values NR<br />

G2: none<br />

N at enrollment:<br />

G1: 22<br />

G1a: 6<br />

G1b: 5<br />

G1c: 5<br />

G1d: 6<br />

G2: 25<br />

G2a: 7<br />

G2b: 5<br />

G2c: 6<br />

G2d: 7<br />

N at follow-up:<br />

G1: 22<br />

G1a: 6<br />

G1b: 5<br />

G1c: 5<br />

G1d: 6<br />

G2: 25<br />

G2a: 7<br />

G2b: 5<br />

G2c: 6<br />

G2d: 7<br />

Intervention:<br />

Phase I: Application of<br />

lotion that contained<br />

glutathione or placebo 1x<br />

per day after bath, with<br />

child rubbing it on <strong>for</strong> 7<br />

days; all children received<br />

oral DMSA at 10 mg/kg 3x<br />

per day <strong>for</strong> 3 days<br />

Phase II: children then<br />

received either DMSA or<br />

placebo <strong>for</strong> up to 3 rounds<br />

(each round consisted of<br />

3 days followed by 11<br />

days of no DMSA/<br />

placebo)<br />

• <strong>Children</strong> who received<br />

Inclusion/ Exclusion<br />

Criteria/ Population<br />

Inclusion criteria:<br />

Phase I:<br />

• Age 3-8 years<br />

• ASD, diagnosed by a<br />

psychiatrist, psychologist,<br />

or developmental<br />

pediatrician<br />

• No mercury amalgam<br />

dental fillings<br />

• No previous DMSA or<br />

other prescription<br />

chelators<br />

• No anemia or currently<br />

being treated <strong>for</strong> anemia<br />

due to low iron<br />

• No known allergies to<br />

DMSA<br />

C-27<br />

Baseline<br />

Measures Outcomes<br />

Overall ratings:<br />

ATEC SPLC, mean ±<br />

SD:<br />

G1: 13.4 ± 7.7<br />

G2: 12 ± 8.4<br />

ATEC Total, mean ±<br />

SD:<br />

G1: 80.8 ± 24<br />

G2: 66.2 ± 20.7<br />

AWP/C composite<br />

(sensory + ritual +<br />

social pragmatic +<br />

semantic + arousal +<br />

fears + aggressive),<br />

mean ± SD:<br />

G1: 105 ± 58.6<br />

(n=25)<br />

Modifiers<br />

15 children in G1<br />

mastered lessons<br />

in the software<br />

program during<br />

the 3 month study<br />

period; no<br />

significant<br />

difference in<br />

Brigance scores<br />

between these<br />

children and the 7<br />

G1 children who<br />

did not master a<br />

lesson.<br />

Significant<br />

correlation<br />

between time<br />

spent on the<br />

software and the<br />

total number of<br />

lessons mastered<br />

in G1 (P = 0.01)<br />

Overall ratings:<br />

ATEC SPLC,<br />

mean ± SD:<br />

G1: 10.6 ± 7<br />

G2: 10.5 ± 8.9<br />

G1/BL: P <<br />

0.001<br />

G2/BL: P = NS<br />

ATEC Total,<br />

mean ± SD:<br />

G1: 60.14 ± 27.9<br />

G2: 53.4 ± 23.5<br />

G1/BL: P <<br />

0.001<br />

G2/BL: P < 0.01<br />

AWP/C<br />

composite, mean

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!